<DOC>
	<DOC>NCT01018563</DOC>
	<brief_summary>An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.</brief_summary>
	<brief_title>An Open Label Extension Study of the Efficacy of MORAb-003</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<criteria>Provision of Informed consent Subjects must have been enrolled in and have met the inclusion/exclusion criteria of the MORAb003002 study. Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or stable disease and an investigator's assessment of a clinical benefit) after MORAb003 in combination with standard chemotherapy and have not yet met the criteria for disease progression during participation in the MORAb003002 study. Subjects must be currently receiving singleagent MORAb003 maintenance therapy. Subjects that discontinued the MORAb003002 study for any reason.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Extension study</keyword>
	<keyword>Epithelial ovarian cancer</keyword>
</DOC>